Patents by Inventor Klimentina Dimitrova Pencheva

Klimentina Dimitrova Pencheva has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polymorph of (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-D]pyrimidin-7-yl)cyclopentane-1,2-diol
    Publication number: 20240116937
    Abstract: This invention relates to crystalline free base forms of (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol, and to compositions and therapeutic uses thereof.
    Type: Application
    Filed: July 8, 2021
    Publication date: April 11, 2024
    Applicant: Pfizer Inc.
    Inventors: Wesley Dewitt Clark, Klimentina Dimitrova Pencheva
  • Crystalline forms of lorlatinib maleate
    Patent number: 11926636
    Abstract: This invention relates to new crystalline forms of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile(lorlatinib) maleate. The invention also relates to pharmaceutical compositions comprising lorlatinib maleate, and to methods of using lorlatinib maleate and compositions comprising it in the treatment of abnormal cell growth, such as cancer, in mammals.
    Type: Grant
    Filed: July 1, 2021
    Date of Patent: March 12, 2024
    Assignee: Pfizer Inc.
    Inventor: Klimentina Dimitrova Pencheva
  • Compounds and methods for the treatment of COVID-19
    Patent number: 11926642
    Abstract: The invention relates to compounds of formula I wherein R1, R2 and - - - - - are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.
    Type: Grant
    Filed: July 1, 2021
    Date of Patent: March 12, 2024
    Assignee: Pfizer inc.
    Inventors: Robert Steven Kania, Padmavani Bezawada, Emma Louise Hawking, Rohit Jaini, Samir Kulkarni, Matthew Nathan O'Brien Laramy, Jonathan Richard Lillis, Suman Luthra, Dafydd Rhys Owen, Klimentina Dimitrova Pencheva, Anil Mahadeo Rane, Matthew Forrest Sammons, Bradley Paul Sullivan, Andrew John Thiel, Martyn David Ticehurst, Jamison Bryce Tuttle, Robert Louis Hoffman
  • Polymorphs of (1S,2S,3S,5R)-3-((6-(Difluoromethyl)-5-Fluoro-1,2,3,4-Tetrahydroisoquinolin-8-YL)OXY)-5-(4-Methyl-7H-Pyrrolo[2,3-D]Pyrimidin-7-YL)Cyclopentane-1,2-DIOL Mono-Hydrochloride
    Publication number: 20230242539
    Abstract: This invention relates to crystalline mono-HCl salt forms of (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol, and to compositions and therapeutic uses thereof.
    Type: Application
    Filed: July 8, 2021
    Publication date: August 3, 2023
    Applicant: Pfizer Inc.
    Inventors: Michael Heberlein, Klimentina Dimitrova Pencheva, Michelle Bich Tran-Dubé
  • Methods of Inhibiting SARS-CoV-2 Replication and Treating Corona Virus Disease 2019
    Publication number: 20230157998
    Abstract: The invention relates to methods of treating COVID-19 in a patient by administering therapeutically effective amounts of certain SARS-CoV-2 inhibitor compounds or pharmaceutical compositions containing them to a patient in need thereof.
    Type: Application
    Filed: March 3, 2021
    Publication date: May 25, 2023
    Applicant: Pfizer Inc.
    Inventors: Padmavani Bezawada, Benjamin Joseph Burke, Emma Louise Hawking, Robert Louis Hoffman, Robert Steven Kania, Jonathan Richard Lillis, Matthew Nathan O'Brien Laramy, Klimentina Dimitrova Pencheva, Bradley Paul Sullivan, Andrew John Thiel, Martyn David Ticehurst
  • Compounds and Methods for the Treatment of COVID-19
    Publication number: 20220017548
    Abstract: The invention relates to compounds of formula I wherein R1, R2 and - - - - - are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.
    Type: Application
    Filed: July 1, 2021
    Publication date: January 20, 2022
    Applicant: Pfizer Inc.
    Inventors: Robert Steven Kania, Padmavani Bezawada, Emma Louise Hawking, Rohit Jaini, Samir Kulkarni, Matthew Nathan O'Brien Laramy, Jonathan Richard Lillis, Suman Luthra, Dafydd Rhys Owen, Klimentina Dimitrova Pencheva, Martin Youngjin Pettersson, Anil Mahadeo Rane, Matthew Forrest Sammons, Bradley Paul Sullivan, Andrew John Thiel, Martyn David Ticehurst, Jamison Bryce Tuttle, Robert Louis Hoffman
  • CRYSTALLINE FORMS OF LORLATINIB MALEATE
    Publication number: 20210388000
    Abstract: This invention relates to new crystalline forms of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile (lorlatinib) maleate. The invention also relates to pharmaceutical compositions comprising lorlatinib maleate, and to methods of using lorlatinib maleate and compositions comprising it in the treatment of abnormal cell growth, such as cancer, in mammals.
    Type: Application
    Filed: July 1, 2021
    Publication date: December 16, 2021
    Applicant: Pfizer Inc.
    Inventor: Klimentina Dimitrova Pencheva
  • Crystalline forms of lorlatinib maleate
    Patent number: 11078215
    Abstract: This invention relates to new crystalline forms of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile(lorlatinib) maleate. The invention also relates to pharmaceutical compositions comprising lorlatinib maleate, and to methods of using lorlatinib maleate and compositions comprising it in the treatment of abnormal cell growth, such as cancer, in mammals.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: August 3, 2021
    Assignee: Pfizer Inc.
    Inventor: Klimentina Dimitrova Pencheva
  • Crystalline form of lorlatinib free base
    Patent number: 11020376
    Abstract: This invention relates to acrystalline form of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-5-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h] [2,5,11]benzoxadiazacyclo-tetradecine-3-carbonitrile (lorlatinib) free base (Form 7). This invention also relates to pharmaceutical compositions comprising Form 7, and to methods of using Form 7 and such compositions in the treatment of abnormal cell growth, such as cancer, in a mammal.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: June 1, 2021
    Assignee: Pfizer Inc.
    Inventors: Klimentina Dimitrova Pencheva, Melissa Jane Birch, Stephen Mark McAllister, Martin Gregory Rowland, Ian Leonard Smales
  • CRYSTALLINE FORMS OF LORLATINIB MALEATE
    Publication number: 20200325155
    Abstract: This invention relates to new crystalline forms of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3- h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile(lorlatinib) maleate. The invention also relates to pharmaceutical compositions comprising lorlatinib maleate, and to methods of using lorlatinib maleate and compositions comprising it in the treatment of abnormal cell growth, such as cancer, in mammals.
    Type: Application
    Filed: March 27, 2017
    Publication date: October 15, 2020
    Applicant: Pfizer Inc.
    Inventor: Klimentina Dimitrova Pencheva
  • CRYSTALLINE FORM OF LORLATINIB FREE BASE
    Publication number: 20190365712
    Abstract: This invention relates to acrystalline form of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-5-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h] [2,5,11]benzoxadiazacyclo-tetradecine-3-carbonitrile (lorlatinib) free base (Form 7). This invention also relates to pharmaceutical compositions comprising Form 7, and to methods of using Form 7 and such compositions in the treatment of abnormal cell growth, such as cancer, in a mammal.
    Type: Application
    Filed: August 8, 2019
    Publication date: December 5, 2019
    Applicant: Pfizer Inc.
    Inventors: Klimentina Dimitrova Pencheva, Melissa J. Birch, Mark McAllister, Martin Rowland, Ian Leonard Smales
  • Crystalline form of lorlatinib free base
    Patent number: 10420749
    Abstract: This invention relates to a crystalline form of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-5-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h] [2,5,11]benzoxadiazacyclo-tetradecine-3-carbonitrile (lorlatinib) free base (Form 7). This invention also relates to pharmaceutical compositions comprising Form 7, and to methods of using Form 7 and such compositions in the treatment of abnormal cell growth, such as cancer, in a mammal.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: September 24, 2019
    Assignee: Pfizer Inc.
    Inventors: Klimentina Dimitrova Pencheva, Melissa J. Birch
  • CRYSTALLINE FORM OF LORLATINIB FREE BASE
    Publication number: 20180235933
    Abstract: This invention relates to acrystalline form of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-5-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h] [2,5,11]benzoxadiazacyclo-tetradecine-3-carbonitrile (lorlatinib) free base (Form 7). This invention also relates to pharmaceutical compositions comprising Form 7, and to methods of using Form 7 and such compositions in the treatment of abnormal cell growth, such as cancer, in a mammal.
    Type: Application
    Filed: July 27, 2016
    Publication date: August 23, 2018
    Applicant: Pfizer Inc.
    Inventors: Klimentina Dimitrova Pencheva, Melissa J. Birch